We first tested a panel of inhibitors of the KMT2A::AFF1 cofactor Menin-1 (MI), covering a range of chemical structures, with the aim of defining the compound with stronger activity in t(4;11) pro-B-ALL cells. This evidence concerns the gene MEN1 and acute lymphoblastic leukemia.